Selected Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended																	12 Months Ended
	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	[1]	Sep. 30, 2017	[1]	Jun. 30, 2017	[1]	Mar. 31, 2017	[1]	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Selected Quarterly Financial Information (Unaudited) [Abstract]
REVENUE	$ 69,697		$ 67,881	$ 71,139	$ 67,505	$ 67,799	$ 64,598	$ 68,496	$ 61,948	$ 52,826		$ 43,999		$ 47,818		$ 45,059		$ 276,222		$ 262,841		$ 189,702
GROSS MARGIN	46,552		45,222	46,966	44,273	45,191	42,714	45,851	39,228	36,363		29,862		32,905		29,512		183,013		172,984		128,642
NET (LOSS) INCOME	$ (681)		$ (134)	$ 2,832	$ (297)	$ (776)	$ 1,565	$ 226	$ (3,855)	$ (3,007)		$ 1,325		$ 3,163		$ 2,223		$ 1,720		$ (2,840)		$ 3,704
(LOSS) INCOME PER COMMON SHARE — DILUTED	$ (0.02)		$ 0.00	$ 0.07	$ (0.01)	$ (0.02)	$ 0.04	$ 0.01	$ (0.11)	$ (0.09)		$ 0.04		$ 0.09		$ 0.06		$ 0.05	[2]	$ (0.08)	[2]	$ 0.11	[2]

[1] In December 2017 we completed our acquisition of JOTEC, which is operated as a wholly-owned subsidiary of CryoLife.

[2] We excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares, because the inclusion of these stock options would be antidilutive to (loss) income per common share. For the year ended December 31, 2018 all stock options and awards were excluded from the calculation of weighted-average common shares outstanding as these would be antidilutive to the net loss. For the years ended December 31, 2019 and 2017 stock options to purchase 131,000 and 227,000 shares, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.